Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-Diarylimidazoles

Journal of Medicinal Chemistry

Volumn 46, Issue 16, 2003, Pages 3463-3475

  Almansa, Carmen ^a   Alfón, José ^a   De Arriba, Alberto F ^a   Cavalcanti, Fernando L ^a   Escamilla, Ignasi ^a   Gómez, Luis A ^a   Miralles, Agustí ^a   Soliva, Robert ^a   Bartrolí, Javier ^a   Carceller, Elena ^a   Merlos, Manuel ^a   García Rafanell, Julián ^a  

^a Grupo Uriach   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 CHLORO 5 (3 FLUORO 4 METHOXYPHENYL)IMIDAZOL 1 YL]BENZENESULFONAMIDE; CELECOXIB; CIMICOXIB; CYCLOOXYGENASE 2 INHIBITOR; IMIDAZOLE DERIVATIVE; INDOMETACIN; ROFECOXIB; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; PAW EDEMA; PHASE 1 CLINICAL TRIAL; RAT; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BINDING SITES; CELL LINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; HUMANS; IMIDAZOLES; INFLAMMATION; ISOENZYMES; MALE; MEMBRANE PROTEINS; MODELS, MOLECULAR; PAIN MEASUREMENT; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0042343839     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030765s     Document Type: Article

References (51)

1. (a) Vane, J. R. Inhibition of Prostaglandin Synthesis as a Mechanism of Action of Aspirin-like Drugs. Nature 1971, 231, 232-5.
2. (b) Vane, J. R.; Ferreira, S. H. Antiinflammatory Drugs; Springer-Verlag: Berlin, 1979; pp 305-347.
3. (a) Sontag, S. J. Prostaglandins in Peptic Ulcer Disease. An Overview of Current Status and Future Directions. Drugs 1986, 32, 445-457.
4. (b) Allison, M. C.; Howatson, A. G.; Torrance, C. J.; Lee, F. D.; Russell, R. Y. G. Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med. 1992, 327, 749-754.
5. Clive, D. M.; Stoff, J. S. Renal Syndromes Associated with Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med. 1984, 310, 563-572.
6. (a) Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a Mitogen-responsive Gene Encoding Prostaglandin Synthase is Regulated by mRNA Splicing. Proc. Natl. Acad. Sci. U.S.A., 1991, 88, 2692-2696.
7. (b) Jujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, a Phorbol Ester Tumor Promoter-Inducible mRNA from Swiss 3T3 Cells, Encodes a Novel Prostaglandin Synthase/Cyclooxygenase Homologue. J. Biol. Chem. 1991, 266, 12866-72.
8. (a) Vane, J. R. Towards a Better Aspirin. Nature, 1994, 367, 215-16.
9. (b) Masferrer, J. L.; Zweifel, B. S.; Manning, P. T. Selective Inhibition of Inducible Cyclooxygenase-2 in vivo is Antiinflammatory and Nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3228-32.
10. Leblanc, Y.; Black, W. C.; Chan, C. C.; Charleson, S.; Delorme, D.; Denis, D.; Gauthier, J. Y.; Grimm, E. L.; Gardon, R.; Guay, D.; Hamel, P.; Kargman, S.; Lau, C. K.; Mancini, J.; Ouellet, M.; Percival, D.; Roy, P.; Skorey, K.; Tagari, P.; Vickers, P.; Wong, E.; Xu, L.; Prasit, P. Synthesis and Biological Evaluation of Both Enantiomers of L-761,000 as Inhibitors of Cycloogygenase 1 and 2. Biorg. Med. Chem. Lett. 1996, 6, 731-6.
11. Kalgutkar, A. S. Selective Cyclooxygenase-2 Inhibitors as Nonulcerogenic Anti-inflammatory Agents. Exp. Opin. Ther. Pat. 1999, 9, 831-849.
12. (a) Reitz, D. B.; Isakson, P. C. Cyclooxygenase-2 Inhibitors. Current Pharm. Design 1995, 1, 211-220.
13. (b) Carter, J. S. Recently Reported Inhibitors of Cyclooxygenase-2. Exp. Opin. Ther. Pat. 1997, 8, 21-29.
14. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
15. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, Y.; Tagari, P.; Thérien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zamboni, R. The Discovery of Rofecoxib, [MK 966, Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)furanone], an Orally Active Cyclooxygenase-2 Inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
16. (a) Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777;
17. (b) Talley, J. J.; Bertershaw, S. R.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Kellogg, M. S.; Koboldt, C. M.; Yuan, J.; Zhang, Y. Y.; Seibert, K. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration. J. Med. Chem. 2000, 43, 1661-1663.
18. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dubé, D.; Ethier, D.; Falgueyret, J. P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, J.; Mancini, J.; Oellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girard, Y.; Prasit, P.; Zamboni, R.; Rodger, I. W.; Gresser, M.; Ford. Hutchinson, A. W.; Young, R. N.; Can, C. C. Etoricoxib (MK-0663): Preclinical Profile and Comparison with other Agents that Selectively Inhibit Cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
19. (a) Jackson, L. M.; Hawkey, C. J. Gastrointestinal effects of COX-2 Inhibitors. Exp. Opin. Invest. Drugs, 1999, 8, 963-971;
20. (b) Breyer, M. D.; Hao, C.; Qi, Z. Cyclooxygenase-2 selective inhibitors and the kidney. Curr. Opin. Crit. Care 2001, 7, 393-400;
21. Emery, P. Cyclooxygenase-2: A Major Therapeutic Advance? Am. J. Med. 2001, 110, 42s-45s.
22. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural Basis for Selective Inhibition of Cyclooxygenase-2 by Anti-inflammatory Agents. Nature 1996, 384, 644-48.
23. Soliva, R.; Almansa, C.; Kalko, S. G.; Luque, F. J.; Orozco, M. Theoretical studies on the inhibition mechanism of COX-2. Is there a unique recognition site? J. Med. Chem., in press.
24. Plount Price, M. L.; Jorgensen, W. L. Analysis of Binding Affinities for Celecoxib Analogues with COX-1 and COX-2 from Combined Docking and Monte Carlo Simulations and Insight into the COX-2/COX-1 Selectivity. J. Am. Chem. Soc. 2000, 122, 9455-9466.
25. Barta, T. E.; Stealy, M. A.; Collins, P. W.; Weier, R. M. Antiinflammatory 4,5-Diarylimidazoles as Selective Cyclooxygenase Inhibitors. Bioorg. Med. Chem. Lett. 1998, 8, 3443-3448.
26. Khanna, I. K.; Weier, R. M.; Yu, Y.; Xu, X. D.; Koszyk, F. J.; Collins, P. W.; Koboldt, C. M.; Veenhuizen, A. W.; Perkins, W. E.; Casler, J. J.; Masferrer, J. L.; Gregory, S. A.; Seibert, K.; Isakson, P. C. 1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective and Orally Active Antiinflammatory Agents. J. Med. Chem. 1997, 40, 1634-1647.
27. van Leusen, A. M.; Wildeman, J.; Oldenziel O. H. Base_Induced Cycloaddition of Sulfonylmethyl Isocyanides to C,N Double Bonds. Synthesis of 1,5-Disubstituted and 1,4,5-Trisubstituted Imidazoles form Aldimines and Imidoyl Chlorides. J. Org. Chem. 1977, 42, 1153-59.
28. Katritzky, A. R.; Cheng, D.; Musgrave, R. P. Syntheses of Imidazoles and Pyrroles: BetMIC and TosMIC as Complementary Reagents. Heterocycles 1997, 44, 67-70.
29. Giam, C. S.; Kikukawa, K.; Trujillo, D. A. A Convenient Preparation of Alkyl and Arylpyridines. OPPI 1992, 137-140.
30. van Leusen, A. M.; Bouma, R. J.; Possel, O. Phase-Transfer Mono-alkylation of Tosylmethylisocyanide. Tetrahedron Lett. 1975, 40, 3487-8.
31. Begg, G. C.; Grimmett, M. R.; Yu-Man, L. The Synthesis of 2-Alkyl and 2-Acyl-imidazoles by Substitution Methods. Aust. J. Chem. 1973, 26, 415-420.
32. Balaban, I. E.; Pyman, F. L. The Bromo-derivatives of 1-Methylglyoxaline, and the Constitution of Chloroxalmethylin. J. Chem. Soc. 1924, 1564-1572.
33. Kirk, K. L. Facile Synthesis of 2-Substituted Imidazoles. J. Org. Chem. 1978, 22, 4381-2.
34. Szczepankiewicz, B. G.; Heathcock, C. H. Total synthesis of Diplamine, a Cytotoxic Pyridoacridine Alkaloid from a Pacific Tunicate. J. Org. Chem. 1994, 59, 3512-3523.
35. DeVleeschauwer, M.; Gauthier, J. Y. Remarkably Mild and Simple Preparation of Sulfinates, Sulfonyl Chlorides and Sulfonamides from Thioanisoles. Synlett 1997, 375-6.
36. Ito, S.; Tanaka, Y.; Kakehi, A. Base-induced Dehydrosulfinatocyclization of N-Alkyl-N-phenylsulfonyl-N″-arylbenzamidrazones to 3,4-Diaryl-4H-1,2,4-triazoles. Bull. Chem. Soc. Jpn. 1984, 57, 544-547.
37. Experimental methods described in Almansa, C.; de Arriba, A. F.; Cavalcanti, F. L.; Gómez, L. A.; Miralles, A.; Merlos, M.; García-Rafanell, J.; Forn, J. Synthesis and SAR of a New Series of COX-2-Selective Inhibitors: Pyrazolo[1,5-a]pyrimidines. J. Med. Chem. 2001, 44, 350-361.
38. Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase-2 in Inflammation and Pain. Natl. Acad. Sci. U.S.A. 1994, 91, 12013-12017.
39. Hargreaves, K.; Dubner, R.; Brown, F.; Flores, C.; Joris, J. A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia. Pain 1988, 32, 77-88.
40. Li, C. S.; Brideau, C.; Chan, C. C.; Savoie, C.; Claveau, D.; Charleson, S.; Gordon, R.; Greig, G.; Gauthier, J. Y.; Lau, C. K.; Riendeau, D.; Therien, M.; Wrong, E. Poster Communication, Presented at the 216th American Chemical Society National Meeting, Boston, 1998.
41. Li, C. S.; Black, W. C.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W. A.; Claveau, D.; Gauthier, J. Y.; Gordon, R.; Greig, G.; Grimm, E.; Guay, J.; Lau, C. K.; Therien, M.; Visco, D. M.; Wong, E.; Xu, L.; Prasit, P. A New Structural Variation on the Methanesulphonylphenyl Class of Selective Cyclooxygenase-2 Inhibitors. Bioorg. Med. Chem. Lett. 1999, 3181-3186.
42. Pinto, D. J. P.; Copeland, R. A.; Covington, M. B.; Pitts, W. J.; Batt, D. G.; Orwat, M. J.; Lam, G. N.; Joshi, A.; Chan, Y.-C.; Wang, S.; Trzaskos, J. M.; Magolda, R. L.; Kornhauser, D. M. Chemistry and Pharmacokinetics of Diarylthiophenes and Terphenyls as Selective Cyclooxygenase-2 Inhibitors. Bioorg. Med. Chem. Lett. 1996, 2907-2912.
43. Menassé-Gdynia R., Krupp P. Quantitative measurement of gastrointestinal bleeding in rats: The effect ofnonsteroidal anti-inflammatory drugs. Toxicol. Appl. Pharmacol. 1974, 29, 389-396.
44. Standard in vitro CYP inhibition ofisoforms CYP2C9, CYP2C19, CYP2D6, and CYP3A4 was performed. For a reference see: Miller V. P.; Stresser D. M.; Blanchard A. P.; Turner S.; Crespi C. L.; Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann. N. Y. Acad. Sci. 2000, 919, 26-32.
45. (a) Almansa, C.; Alfón, J.; Cavalcanti, F. L.; Escamilla, I.; Gómez, L. A.; Miralles, A. Discovery of UR-8880: A New COX-2 Selective Inhibitor. Poster Communication, 222nd ACS National Meeting, Chicago, 2001.
46. (b) Almansa, C.; González, C.: Torres, C. Patent Appl. WO 0023426.
47. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
48. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J.; Impey, R. W.; Klein, M. L. Comparison of Sample Potential Functions for Simulating Liquid Water. J. Chem. Phys. 1983, 79, 926-933.
49. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson MD.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids and Organic Molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
50. Ponder, J. W. TINKER, Software Tools for Molecular Design.
51. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes. J. Comput. Phys. 1977, 23, 327-341.